GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
ustekinumab-auub; ABP 654Wezlana; WezenlaAmgenApproved (2023 FDA, 2024 EMA)As per reference agent; Interchangeable with reference agent
ustekinumab-aekn; AVT04Selarsdi; UzpruvoAlvotech/Teva Pharmaceuticals/STADA ArzneimittelApproved (2024 FDA & EMA)As per reference agent
ustekinumab-ttwe; SB17Pyzchiva; Epyztek; EksunbiSandoz/Samsung BioepisApproved (2024 FDA, EMA and S Korea MFDS)As per reference agent; Interchangeable with reference agent*
ustekinumab; CT-P43SteQeymaCelltrionApproved (2024 EMA)As per reference agent
ustekinumab-aauz; FYB202Otulfi; Fymskina Fresenius Kabi/Formycon Approved (2024 EMA & FDA)As per reference agent; available as subcutaneous and intravenous formulations
ustekinumab-srlf; DMB-3115Imuldosa/AbsimkyAccord BioPharma/Intas PharmaceuticalsApproved (2024 EMA & FDA)As per reference agent
ustekinumab-kfce; Bmab1200Yesintek Biocon BiologicsApproved (2024 FDA, 2025 EMA)As per reference agent
ustekinumab-hmny; BAT2206StarjemzaBio-Thera Solutions/Hikma PharmaceuticalsApproved (2025 FDA)As per reference agent

*After expiry of the period of exclusivity for the first interchangeable biosimilar product.
No information available.
Summary of Clinical Use Click here for help
Used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Ustekinumab binds to the IL-12B component of the dimeric cytokines IL-12 and IL-23. This action supresses the activation of certain T-cells, thereby dampening the immune response.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)